Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and
safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with
Tourette Disorder according to DSM IV criteria. The primary efficacy measure will be the
Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS) at 6 weeks.